Search
EHA-EMN Joint Session at the European Myeloma Network Meeting EMN2023
On Saturday, 22 April, EHA and EMN brought together patients, regulators and clinicians to discuss Novel Endpoints in Multiple Myeloma.
Read moreImmunoglobulin shortages in the spotlight: EMA, SUPPLY and the SoHO Regulation
EMA executive director Emer Cooke welcoming participants including EHA at the Shortages Workshop, March 1
Shortages of immunoglobulins and the need to increase and sustain plasma supplies have moved to the center of the EU policy and regulatory stage.
New HemaSphere publication on IVDR implementation
The In Vitro Diagnostic medical devices Regulation (IVDR), which came in to force in May 2022 with the objective of safeguarding the quality and safety of diagnostic tests in the EU, has a major impact on commercially available IVDs (CEIVDs) and…
Read moreEU pilot on drug repurposing
Drug repurposing (finding new indications for existing authorized medicines) is increasingly prominent in the debate about improving access to medicines. As stated in EHA’s position paper on access to affordable orphan medicines (Merlini et al.
Read moreThe EHA Guidelines Workshop, a meaningful and successful first Series!
November 2020 – April 2021
In the past six months, hematologists, clinicians, transfusion medicine specialists, oncologists, special nurses and researchers gathered virtually for the first EHA Guidelines Workshop series.
Starting this November: EHA Guidelines Workshops!
EHA has initiated a series of online workshops dedicated to guidelines (produced or endorsed by EHA) for diagnosis and treatment of hematologic diseases.
Read moreReducing bureaucracy in clinical trials: now is the time!
Medical societies and patient advocates across disciplines have joined forces with EHA to call for urgent action to make clinical trials less bureaucratic and more patient-centered, efficient and cheaper.
Read more